No results found for “”
No results found for filter “”
-
EFPIA News 29.01.25
Medicine shortages: EFPIA proposal for action
Together, all stakeholders share a responsibility and commitment to building resilient supply chains that ensure patients receive the medicines they need....
Read Article -
Statements & press releases 29.01.25
EFPIA response to the European Commission’s ‘Competitiveness Compass’
EFPIA welcomes the publication of the Competitiveness Compass and the recognition of the role that innovation in life sciences can play in reigniting EU...
Read Article -
EFPIA News 24.01.25
EFPIA response to the adoption of the European Health Data Space (EHDS)
EFPIA welcomes the adoption of the European Health Data Space (EHDS) by the Council of the EU, marking a significant step forward in leveraging health...
Read Article -
Blog articles 22.01.25
Unmet Medical Needs (UMN): the case of Alpha-Mannosidosis
An interview with Giorgio Iotti, Vice President, R&D Pipeline & Portfolio, Rare Diseases, Chiesi Group
Read Article -
EFPIA News 15.01.25
IMAGINE if Europe was a leader in life sciences
Just imagine if the EU Life Sciences Sector developed the next generation of therapies, attracted the best scientific research, developed the brightest...
Read Article -
Blog articles 15.01.25
Patient-centered innovation: Can Europe lead the way?
We can’t make true progress on unmet medical needs unless we understand what the patients themselves think they need or say is missing from their treatment...
Read Article -
EFPIA News 08.01.25
With NIRO navigate innovation and research opportunities
2025 has arrived, bringing a host of opportunities for R&I! Find which one(s) could best help you pursue groundbreaking work.
Read Article -
Statements & press releases 08.01.25
DIGITAL LEAP: Industry Proposes Phased Rollout of ePI for Patient Safety and Environmental Sustainability...
By transitioning to ePI, patients, healthcare professionals (HCPs), and civil society will benefit from the most up-to-date, accessible medicinal information,...
Read Article -
Blog articles 11.12.24
The origins and privileges of self-regulation
Self-regulation plays a vital role in governing how pharmaceutical companies promote medicines, interact with health professionals and collaborate with...
Read Article -
Statements & press releases 10.12.24
Patients and society set to benefit from innovation which could “alleviate significant global disease...
The Pipeline review is an important reminder that many people continue to live with debilitating and life limiting disease, for whom new medicines could...
Read Article -
Blog articles 09.12.24
EFPIA response to ‘Guidance on outcomes for joint clinical assessments’
We remain optimistic that the flexibility included in the guideline is applied by the assessors in a pragmatic approach. Looking into the future, we hope...
Read Article -
Statements & press releases 05.12.24
9 ways to maximise the impact of the future EU Framework Programme for Research and Innovation (FP10) ...
Ahead of the discussions on the EU future Framework Programme for Research and Innovation (FP10), EFPIA is putting forward nine recommendations to help...
Read Article
No results found for “”
No results found for filter “”
-
EFPIA News 29.01.25
Medicine shortages: EFPIA proposal for action
Together, all stakeholders share a responsibility and commitment to building resilient supply chains that ensure patients receive the medicines they need....
Read Article -
EFPIA News 24.01.25
EFPIA response to the adoption of the European Health Data Space (EHDS)
EFPIA welcomes the adoption of the European Health Data Space (EHDS) by the Council of the EU, marking a significant step forward in leveraging health...
Read Article -
EFPIA News 15.01.25
IMAGINE if Europe was a leader in life sciences
Just imagine if the EU Life Sciences Sector developed the next generation of therapies, attracted the best scientific research, developed the brightest...
Read Article -
EFPIA News 08.01.25
With NIRO navigate innovation and research opportunities
2025 has arrived, bringing a host of opportunities for R&I! Find which one(s) could best help you pursue groundbreaking work.
Read Article -
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
EFPIA News 26.09.24
EFPIA position on opt-out in the EHDS Regulation
EFPIA stresses the importance of avoiding fragmentation and bias, clarifying the scope of the opt-out by limiting it to personal data and creating a centralised...
Read Article -
EFPIA News 11.07.24
NIRO: Navigating innovation and research opportunities
A new tool to help navigate the complex world of health R&I funding programmes.
Read Article -
EFPIA News 08.07.24
Breaking down barriers: Making cross-border access to clinical trials a reality
Collaborative effort by EFGCP and EFPIA develops action plan to address participation barriers in Europe
Read Article -
EFPIA News 12.06.24
New data from EFPIA reveals multiple factors leading to unequal access to medicines for patients across...
"Whatever the reason, whatever the cause, we stand ready to play our part in reducing the time it takes for patients to access the medicines we discover,...
Read Article -
EFPIA News 04.06.24
Insights from EFPIA's Reliance Webinar
On the 19th of March EFPIA have hosted a joint industry webinar on Reliance, providing a platform for information and discussion on use of EMA assessment...
Read Article -
EFPIA News 26.04.24
Journal article - Evolving assessment pathways for precision oncology medicines to improve patient access:...
This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an...
Read Article -
EFPIA News 26.04.24
White paper on circular economy
Continued adoption of circular economy principles into the pharmaceutical sector can reduce materials extraction and operational waste, contribute to a...
Read Article
No results found for “”
No results found for filter “”
-
Statements & press releases 29.01.25
EFPIA response to the European Commission’s ‘Competitiveness Compass’
EFPIA welcomes the publication of the Competitiveness Compass and the recognition of the role that innovation in life sciences can play in reigniting EU...
Read Article -
Statements & press releases 08.01.25
DIGITAL LEAP: Industry Proposes Phased Rollout of ePI for Patient Safety and Environmental Sustainability...
By transitioning to ePI, patients, healthcare professionals (HCPs), and civil society will benefit from the most up-to-date, accessible medicinal information,...
Read Article -
Statements & press releases 10.12.24
Patients and society set to benefit from innovation which could “alleviate significant global disease...
The Pipeline review is an important reminder that many people continue to live with debilitating and life limiting disease, for whom new medicines could...
Read Article -
Statements & press releases 05.12.24
9 ways to maximise the impact of the future EU Framework Programme for Research and Innovation (FP10) ...
Ahead of the discussions on the EU future Framework Programme for Research and Innovation (FP10), EFPIA is putting forward nine recommendations to help...
Read Article -
Statements & press releases 05.12.24
Pharmaceutical innovators are concerned over not enough advice meetings being offered in 2025 for discussing...
From 12 January 2025 the EU HTA Regulation will apply and the first JCAs will be performed to assess the relative clinical effectiveness of new innovative...
Read Article -
Statements & press releases 03.12.24
EFPIA response to EPSCO meeting
Today’s EPSCO meeting covered a number of health files. EFPIA particularly welcomes the adoption of council conclusions on cardiovascular health. With...
Read Article -
Statements & press releases 26.11.24
Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA
SMEs are critical to the future of European life sciences and patients. We need policymakers to get behind an ambitious strategic vision for the competitiveness...
Read Article -
Statements & press releases 13.11.24
Despite a decade of gradual growth, R&D spending in Europe outpaced by the US – with increasing competition...
Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy...
Read Article -
Statements & press releases 05.11.24
Joint statement from the human pharmaceutical industry on the Urban Wastewater Treatment Directive (UWWTD)...
EFPIA and AESGP, representing the human pharmaceutical industry in Europe, acknowledge, with some reservations, the approval by the Council of the European...
Read Article -
Statements & press releases 22.10.24
60,000 fewer clinical trial places for Europeans, despite global surge in research projects.
"For Europe to be competitive, it needs to function as a unified region" says Nathalie Moll.
Read Article -
Statements & press releases 18.10.24
EFPIA position on the Urban Wastewater Treatment Directive
EFPIA, its member companies and national associations are concerned by the impact that the Urban Wastewater Treatment Directive will have on European patients...
Read Article -
Statements & press releases 16.10.24
Coalition of 43 Business Associations Rallies Behind Call for Bold & Open Trade Policy to Keep Europe...
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold...
Read Article
No results found for “”
No results found for filter “”
-
Blog articles 22.01.25
Unmet Medical Needs (UMN): the case of Alpha-Mannosidosis
An interview with Giorgio Iotti, Vice President, R&D Pipeline & Portfolio, Rare Diseases, Chiesi Group
Read Article -
Blog articles 15.01.25
Patient-centered innovation: Can Europe lead the way?
We can’t make true progress on unmet medical needs unless we understand what the patients themselves think they need or say is missing from their treatment...
Read Article -
Blog articles 11.12.24
The origins and privileges of self-regulation
Self-regulation plays a vital role in governing how pharmaceutical companies promote medicines, interact with health professionals and collaborate with...
Read Article -
Blog articles 09.12.24
EFPIA response to ‘Guidance on outcomes for joint clinical assessments’
We remain optimistic that the flexibility included in the guideline is applied by the assessors in a pragmatic approach. Looking into the future, we hope...
Read Article -
Blog articles 04.12.24
Resetting Europe’s Innovation Compass
Europe’s pharmaceutical sector has grown slowly for 25 years and its share of research is shrinking. It’s time to turn things around.
Read Article -
Blog articles 20.11.24
European Antibiotic Awareness Day: Urgent Need for Sustainable Antimicrobial R&D to Combat Superbugs
In Europe alone, antimicrobial resistance or AMR results in 35,000 deaths annually, with healthcare costs and productivity losses estimated at €1.5 billion...
Read Article -
Blog articles 14.11.24
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s...
Read Article -
Blog articles 13.11.24
Filling the Gaps in Care: Driving Change through Embracing Carers® (Guest blog)
Supporting informal carers isn’t just about helping; it’s about elevating entire communities.
Read Article -
Blog articles 10.11.24
Navigating Certainty and Analytical Complexity: Industry’s Reflections on Ensuring Scientific Rigor and...
The HTA Regulation (HTAR) requires that Joint Clinical Assessments (JCAs) describe the certainty of a health technology’s effects by considering the strengths...
Read Article -
Blog articles 29.10.24
Around the world of evidence synthesis (in eighty pages): the methodological and practical guidelines...
Application of the European HTA Regulation is around the corner - in only a few months from now, the first products will go through the new European Joint...
Read Article -
Blog articles 28.10.24
Chasing bold goals to unlock new solutions
Learn more about Timothy Radstake, Vice President and Global Head of Immunology Discovery Research at AbbVie, and his efforts to drive innovation, close...
Read Article -
Blog articles 24.10.24
Let’s dig deeper on Unmet Medical Need (Guest Blog)
Stefan Frings explains why a broad, encompassing definition of Unmet Medical Need, is key in R&D investment decisions.
Read Article